Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- article scientifique publié en 2020 (fr)
- artículu científicu espublizáu en xunu de 2020 (ast)
- наукова стаття, опублікована 10 червня 2020 (uk)
- scientific article published on 10 June 2020 (en)
- 2020 թվականի հունիսի 10-ին հրատարակված գիտական հոդված (hy)
|
publication date
| |
publication date
| |
author name string
| |
author name string
| - Jie Zhang
- Eric Wu
- Hongbo Yang
- James Signorovitch
- Junlong Li
- Qiufei Ma
|
rdfs:label
| - A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? (en)
- A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? (nl)
|
skos:prefLabel
| - A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? (en)
- A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? (nl)
|
name
| - A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? (en)
- A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? (nl)
|
title
| |
title
| - A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? (en)
|
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
DOI
| |
DOI
| |
DOI
| - 10.1007/S12325-020-01397-9
|
PMCID
| |
PMCID
| |
is about
of | |
is cites work
of | |
is cites work
of | |